Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
08 November 2024 | Story Jacky Tshokwe | Photo Supplied
Kingdom Vision Foundation 2024
The Kingdom Vision Foundation (KVF) management team took part in the annual Social Impact Innovation Awards organised by the SAB Foundation.

In September, the Kingdom Vision Foundation (KVF) management team took part in the annual Social Impact Innovation Awards, organised by the SAB Foundation. This competition included a three-day workshop, during which participants received mentorship on enhancing their business models to maximise sustainable impact. Participants also crafted a four-minute business pitch, which they delivered to a panel of independent judges from sectors such as business, health, education, and government. At the end of the workshop, winners were chosen based on the impact of their innovation, the strength of their business model, and the likelihood of future success.

On 10 October, the management team attended the Innovation Awards Ceremony, where KVF was honoured with the Development Award worth R700 000. In addition to the grant, KVF will participate in a 15-month business coaching and mentorship programme in 2025, through which the SAB Foundation’s coaching team will support them in expanding and scaling their impact across South Africa.

The funding will enhance both the Kovsie Health and Anchor of Hope eye clinics, which are collaborating with the University of the Free State (UFS) Department of Optometry to provide affordable eye care to thousands of students and community members. The project aims to improve the quality of education for Optometry students, helping them experience the positive change they can drive through social impact. KVF’s vision includes a future at Kovsie Health where every student’s visual needs are met, regardless of financial constraints, and a thriving Anchor of Hope clinic that brings the gift of sight and renewed hope to rural communities around Bloemfontein.

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept